Rubraca (rucaparib) is a small molecule pharmaceutical. Rucaparib was first approved as Rubraca on 2016-12-19. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 1. Rubraca's patents are valid until 2035-08-17 (FDA).
|Drug Class||Poly-ADP-ribose polymerase inhibitors|